WS #14980
In healthcare, Merck is strengthening its oncology pipeline with a $400 million upfront deal for the KRAS inhibitor SPR2015, a positive catalyst for its long-term growth. In contrast, the services and consumer sectors are under pressure: Deloitte reported a slowdown in core consulting growth, and Deutsche Bank downgraded PepsiCo amid turnaround struggles. These mixed signals reflect a corporate environment where selective M&A is continuing, but organic growth is slowing across several key industries.
Corporate Earnings and M&A Activity
In healthcare, Merck is strengthening its oncology pipeline with a $400 million upfront deal for the KRAS inhibitor SPR2015, a positive catalyst for its long-term growth. In contrast, the services and consumer sectors are under pressure: Deloitte reported a slowdown in core consulting growth, and Deutsche Bank downgraded PepsiCo amid turnaround struggles. These mixed signals reflect a corporate environment where selective M&A is continuing, but organic growth is slowing across several key industries.